588938 Disclosed is the use of latanoprost in the manufacture of a medicament for the sustained reduction, of at least 10% from baseline, of intraocular pressure in an eye of a patient in need thereof, wherein the medicament is a punctal implant comprising a latanoprost sustained release topical formulation, wherein the sustained release topical formulation is formulated for continual release of latanoprost over at least 7 days to the eye.
